Skip to main
BEAT

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam is showing promising results with its expanded commercial launch of hand-held ECG, initiation of a pilot study for 12-lead extended wear patch capable of detecting ischemia, and ahead of schedule patient enrollment for a pilot study on heart attack detection. In addition, the company's strategic collaboration with Mount Sinai and disciplined cost management are positive indicators for future success. However, there are risks involved such as failure in clinical trials, competition, dilution and going concern that should be taken into consideration.

Bears say

HeartBeam is seeing initial success with the commercial launch of their ECG solutions through partnerships with ClearCardio and Atelier Health, targeting a potential ARR opportunity of $75M-$150M in the direct pay segment. Additionally, their innovative 12-lead extended wear patch technology has generated interest in the industry, potentially disrupting the $2B MCT segment with the ability to detect ischemia and utilizing existing reimbursement codes. The company's recent pilot study and meetings with larger industry players at major conferences have further bolstered interest in strategic partnerships for bringing the patch to market.

HeartBeam (BEAT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, HeartBeam (BEAT) has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.